Dietary supplement, ear drop ads referred to enforcement agencies
This article was originally published in The Tan Sheet
Executive Summary
The National Advertising Division of the Council of Better Business Bureaus will refer ads for dietary supplement Lipodrene to the Federal Trade Commission and FDA because marketer Hi-Tech Pharmaceuticals failed to respond to a NAD inquiry, the watchdog group reports Oct. 8. NAD challenged a number of the ads' unsubstantiated health-related and weight-loss claims. Separately, the agency will refer advertising for Similasan Corporation USA's Earache Relief Ear Drops to "appropriate federal agencies" after the company refused to comply with certain recommendations in a NAD decision. The agency found the advertiser's clinical studies unreliable and ad claims unsubstantiated. NAD has recently been able to expand dietary supplement reviews in light of grants from the Council for Responsible Nutrition (1"The Tan Sheet" Sept. 25, 2006 p. 7)...
You may also be interested in...
CRN Grants $500K To NAD For Increased Dietary Supplement Monitoring
CRN is committing nearly half a million dollars over a three year period to triple the annual number of dietary supplement cases reviewed by the Council of Better Business Bureaus' National Advertising Division (NAD)
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.